- Home
- LRE vs ACXP Comparison
LRE vs ACXP Comparison
Compare LRE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- ACXP
- Stock Information
- Founded
- LRE 2001
- ACXP 2017
- Country
- LRE Japan
- ACXP United States
- Employees
- LRE 70
- ACXP N/A
- Industry
- LRE
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- ACXP Health Care
- Exchange
- LRE Nasdaq
- ACXP Nasdaq
- Market Cap
- LRE 29.9M
- ACXP 31.4M
- IPO Year
- LRE 2023
- ACXP 2021
- Fundamental
- Price
- LRE $2.23
- ACXP $1.30
- Analyst Decision
- LRE
- ACXP Strong Buy
- Analyst Count
- LRE 0
- ACXP 1
- Target Price
- LRE N/A
- ACXP $12.00
- AVG Volume (30 Days)
- LRE 44.1K
- ACXP 97.1K
- Earning Date
- LRE 01-01-0001
- ACXP 11-12-2024
- Dividend Yield
- LRE N/A
- ACXP N/A
- EPS Growth
- LRE N/A
- ACXP N/A
- EPS
- LRE 0.29
- ACXP N/A
- Revenue
- LRE $117,804,154.00
- ACXP N/A
- Revenue This Year
- LRE N/A
- ACXP N/A
- Revenue Next Year
- LRE N/A
- ACXP N/A
- P/E Ratio
- LRE $7.30
- ACXP N/A
- Revenue Growth
- LRE 8.82
- ACXP N/A
- 52 Week Low
- LRE $1.19
- ACXP $1.18
- 52 Week High
- LRE $13.76
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- LRE 58.84
- ACXP 12.41
- Support Level
- LRE $2.02
- ACXP $1.18
- Resistance Level
- LRE $2.29
- ACXP $1.73
- Average True Range (ATR)
- LRE 0.13
- ACXP 0.12
- MACD
- LRE -0.00
- ACXP -0.05
- Stochastic Oscillator
- LRE 67.35
- ACXP 16.67
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.